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ABSTRACT There is increasing evidence for the important role played by regulatory peptides
in the physiology of the normal and neoplastic prostate. Adrenomedullin (AM) and pro-ad-
renomedullin N-terminal 20 peptide (PAMP) are recently discovered regulatory peptides widely
expressed in the normal prostate and in prostate carcinoma. AM is produced in secretory, stroma,
and endothelial cells and in neurons of the prostate ganglia. PAMP is only produced by neuroen-
docrine cells. The expression of AM mRNA is regulated by androgens in the rat prostate. The
number of neuroendocrine cells expressing PAMP is increased in prostate carcinoma after androgen
deprivation, which shows that this peptide could regulate androgen-independent prostate tumor
growth. However, the roles of AM and PAMP in the normal prostate and in prostate carcinoma are
yet to be elucidated. Microsc. Res. Tech. 57:98–104, 2002. © 2002 Wiley-Liss, Inc.
INTRODUCTION
Human prostate is composed of tubuloalveolar
glands surrounded by fibromuscular stroma (Stamey et
al., 1988). The glands include terminal acini originat-
ing from the branching of ducts connected to the pros-
tatic urethra. The epithelium of the glands is composed
of three types of cells, called secretory or luminal,
basal, and neuroendocrine (NE) cells (reviewed by
Luke and Coffey, 1994). Luminal cells are the most
abundant type and are responsible for the secretory
function of the prostate. Basal cells are considered to
contain the stem cell population, which is able to pro-
liferate for regenerating the epithelial compartment
(Bonkhoff et al., 1994). NE cells are found scattered
among secretory and basal cells and secrete a variety of
peptides that control the biology of other prostatic cells
(reviewed by Abrahamsson, 1999). The prostate is an
androgen-dependent organ which suffers a strong in-
volution after castration. Secretory, basal, and stroma
cells express androgen receptor (Iwamura et al., 1994),
whereas NE cells do not (Abrahamsson, 1999).
Rodents, such as rats and mice, have frequently been
used as models to study the biology and pathology of
the human prostate. Rat and mouse prostate is com-
posed of three distinctive types of lobes called ventral,
dorsal, and lateral lobes. Ventral lobes are the biggest
in size and contain the most developed system of ductal
branches. The glands are organized in ducts emerging
from the urethra and branching to terminal acini
(Jesik et al., 1982). For many years the glandular epi-
thelium was considered to be composed of basal and
secretory cells, but not NE cells (Angelsen et al., 1997).
However, NE cells have recently been described in the
prostate of rodents (Jime´nez et al., 1999; Masumori et
al., 2001). The prostate of rodents shares some similar-
ities with the human prostate, although no spontane-
ous prostate tumors arise in mice or rats (Luke and
Coffey, 1994). However, prostate tumors can be in-
duced by chemical carcinogens or transgenic expres-
sion of oncogenes (Bosland, 1992; Greenberg et al.,
1995).
Prostate carcinoma (PCa) is currently the second-
leading cause of cancer death in men (Parker et al.,
1996). PCa is androgen-dependent in early stages and,
therefore, it can be controlled by androgen ablation.
However, it frequently becomes androgen-insensitive
after androgen withdrawal therapy (Gittes, 1991). This
new status is accompanied by a more aggressive behav-
ior of the tumors and poor prognosis for the patients
because of the lack of effective treatments. It has been
suggested that growth factors secreted by both the
secretory and NE cells might play an important role in
tumor growth, acting in an autocrine or paracrine man-
ner (Abrahamsson, 1999). In particular, peptides se-
creted by NE cells could be critical in tumor growth
after androgen deprivation, since NE cells are andro-
gen-independent (Abrahamsson, 1999). For all these
reasons, there is increasing interest in finding new
molecules that play a role in the normal and tumoral
physiology of the prostate which can be used as targets
for therapy. In this review we present the current in-
formation on adrenomedullin (AM) and pro-adreno-
medullin N-terminal 20 peptide (PAMP), two peptides
originating from the same gene but localized in sepa-
rate compartments in the prostate. The current data
suggest that both peptides could play a key role in
normal and neoplastic prostate.
AM and PAMP are recently discovered regulatory
peptides generated from a 185-amino acid precursor
through enzymatic cleavage (Kitamura et al., 1993;
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Hinson et al., 2000, review). These peptides have been
detected in a large variety of organs and cell types and
exert different roles, depending on the system where
they are localized. AM acts as a vasodilator, autocrine
growth factor or growth inhibitor, neurotransmitter,
and bronchodilator (Hinson et al., 2000). AM also con-
trols hormone secretion and renal homeostasis (Hinson
et al., 2000). PAMP is a vasodilator (Kitamura et al.,
1994) and inhibits neurotransmission (Shimosawa et
al., 1995) and neuroblastoma cell growth (Ando et al.,
1997).
Both AM and PAMP are amidated peptides (Hinson et
al., 2000). Amidation represents an important step in
maturation of many peptides and growth factors in order
to become completely bioactive (Eipper et al., 1992). The
only amidating enzyme described so far is peptidylglycine
alpha-amidating monooxygenase (PAM), which includes
two enzymes acting sequentially, peptidylglycine alpha-
hydroxylating monooxygenase (PHM), and peptidyl-
alpha-hydroxyglycine alpha-amidating lyase (PAL)
(Eipper et al., 1992).
AM and PAMP act on the target cells through differ-
ent receptors. Several AM-receptors have been de-
scribed, some of them also acting as CGRP-receptors
(Hinson et al., 2000). Since AM and PAMP are pluri-
potent peptides, the presence of a particular type of
receptor in a specific cell type will probably determine
the function of AM and/or PAMP.
AM AND PAMP IN THE RAT PROSTATE
AM is Expressed in a Large Variety of Cells in
the Rat Prostate
AM is abundantly expressed in the rat prostate. In
this organ, the expression of AM mRNA is at least
50-fold higher than in the adrenal gland and cardiac
atria (Pewitt et al., 1999), tissues where AM expression
was reported to be high (Sakata et al., 1994). Both the
peptide and the mRNA have been mainly found in the
secretory cells of the glandular epithelium (Jime´nez et
al., 1999; Pewitt et al., 1999). The expression of AM
differs, depending on the prostatic lobe and the portion
of the gland. The lateral lobes contain the highest
amount of peptide and mRNA (Figs. 1, 2) and the ducts
in all the lobes contain higher levels than the acini (as
demonstrated by immunohistochemistry and in situ
hybridization). In the acini of the lateral lobes, AM
peptide is localized in the apical cytoplasm and the
perinuclear area of the secretory cells (Fig. 1). A similar
pattern is observed in the dorsal lobes, whereas in the
ventral prostate the staining is restricted to some scat-
tered cells with apical nucleus. In all the lobes, the
immunostaining found in the ducts is homogeneously
distributed in the cytoplasm of the epithelial cells. A
small population of very intensely AM-labeled cells is
also found scattered throughout the ducts, in all the
prostate lobes, and in the urethra. These cells resemble
NE cells (Jime´nez et al., 1999).
Western blot analysis also shows lobe-specific differ-
ences. A 14-kDa band is found in extracts from the
dorsolateral prostate (mostly including tissue from the
acini). This band corresponds to the AM precursor and
it has been previously described in other organs (Miller
et al., 1996; Jahnke et al., 1997). In extracts from the
ventral lobes (including tissue from the acini and the
ducts), bands of 14-kDa and 6-kDa (fully processed
AM) can be detected. Since the 6-kDa band corresponds
to the active form of AM, it has been suggested that the
ventral lobe could produce more active AM than the
dorsolateral lobes, or that the turnover in the dorsolat-
eral prostate could be faster, thus causing a rapid elim-
ination of the 6-kDa product (Jime´nez et al., 1999).
Besides the epithelial cells of the glands, both in situ
hybridization and immunohistochemistry show that
AM is expressed in other prostate-associated tissues
(Jime´nez et al., 1999). AM is found in the epithelial
cells of the ampullary glands, urethra, ureters, and
ejaculatory ducts and in the endothelial cells of blood
vessels (Fig. 1). Moreover, some stromal cells (mainly
Fig. 1. Immunohistochemical staining
for AM in acini of the lateral prostate. Ep-
ithelial cells and endothelial cells (arrows)
are labeled. 300. [Color figure can be
viewed in the online issue, which is avail-
able at www.interscience.wiley.com.]
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muscle cells) and some neurons of the prostate-associ-
ated ganglia express AM as well. The widespread dis-
tribution of AM in the rat prostate and its localization
in such different cellular types points out that this
peptide could be involved in a large variety of func-
tions. AM receptor has also been found by RT-PCR in
the prostate, although its precise localization is still
unknown. The presence of AM and AM-receptor in rat
prostate suggests an autocrine-paracrine way of action.
It has been demonstrated that AM causes relaxation
of the smooth muscle in the rat prostate, as do also
CGRP and amylin (Ventura et al., 2000), two peptides
that share homology with AM. Since contraction of the
muscular layer surrounding prostate glands facilitates
fluid secretion, AM could regulate epithelial fluid se-
cretion by relaxation of subjacent muscle cells. The
cellular localization of AM also support this role. In
ducts, where there is high expression of AM, the
smooth muscle layer surrounding the glandular epithe-
lium is abundant, whereas in acini, where AM is ex-
pressed at lower levels, the muscular layer is thinner
(Jime´nez et al., 1999).
AM plays a major role in the cardiovascular system.
A strong hypotensive effect via NO generation has been
described as a consequence of AM action (Hirata et al.,
1995). This effect is comparable to that of CGRP (Kita-
mura et al., 1993). In this regard, the expression of AM
in prostate endothelial cells could be related to regula-
tion of prostatic vascular tone.
Expression of PAMP is Restricted to
Neuroendocrine-Like Cells
Unlike the human prostate, the glands of the rat
prostate contain a very small population of NE cells
(Jime´nez et al., 1999). The amount and location of rat
prostatic NE cells make localization difficult. NE cells
are mainly located in the urethra and glandular ducts
proximal to the urethra, although scarce numbers can
be observed in acini. Another different feature with
respect to humans is that in the rat prostate the num-
ber of NE cells positive for chromogranin-A (CgA) is
lower than the number of NE cells positive for seroto-
nin (Jime´nez et al., 1999). Therefore, CgA cannot be
considered a pan-marker for NE cells in the rat pros-
tate. Cells expressing PAMP (Fig. 3) constitute a sub-
population of NE cells expressing serotonin in the rat
prostate, since all of the PAMP-positive cells colocal-
ize with serotonin-positive cells. However, PAMP-
immunoreactive cells do not colocalize with CgA-NE
cells and, for that reason, we named them NE-like cells
(Jime´nez et al., 1999). Four subpopulations of NE cells
(or NE-like cells) can be distinguished in the rat pros-
tate, depending on their immunoreactivity for: 1) sero-
tonin, 2) serotonin and PAMP, 3) serotonin and CgA,
and 4) AM (Jime´nez et al., 1999).
The lack of colocalization of AM and PAMP in the
prostate shows that, in spite of the fact that both pep-
tides originate from the same gene and have a common
mRNA, different posttranscriptional events will deter-
mine which one of these peptides will be expressed by
a specific cell type. Other studies have also shown
separate expression of AM and PAMP in the same
organ (Lopez et al., 1999, in kidney; Montuenga et al.,
2000, in the pituitary). The molecular mechanisms re-
sponsible for this differential expression have to be
elucidated in future studies.
AM Is Regulated by Androgens
in the Rat Prostate
A PCR-based cDNA subtraction method isolated AM
as an androgen response gene in the rat ventral pros-
tate (Wang et al., 1997). The screening was performed
Fig. 2. In situ hybridization of preproAM mRNA in acini of the
lateral prostate. a: A strong signal in the epithelium is detected with
the antisense probe. 250. b: The negative control with the sense
probe gives no staining, thus showing the specificity of the labeling.
500.
Fig. 3. Immunohistochemical staining for PAMP in a duct of the
lateral prostate. The labeling is found in a neuroendocrine cell (ar-
row). 500.
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using mRNA from ventral prostates of 7-day castrated
young male rats and 7-day castrated rats after 14 and
48 hours of androgen replacement. AM was identified
among the upregulated genes after 14 hours of andro-
gen replacement following castration and was there-
fore classified as an early androgen response gene
(Wang et al., 1997).
Further studies by Northern blot analysis demon-
strated a 25-fold decrease in AM mRNA levels in the
prostate of castrated rats with respect to controls, the
decrease occurring mostly within 1 day (Pewitt et al.,
1999). Androgen replacement elevated AM expression
within only 14 hours. The upregulation of AM after
androgen replacement was maintained as long as an-
drogens were present, which confirms that the regula-
tion does not occur transiently. Interestingly, 5-alpha-
dihydrotestosterone (DHT) was able to super-induce
AM expression in primary prostate organ cultures even
in the presence of cycloheximide, a protein synthesis
inhibitor, suggesting that androgens directly stimulate
AM expression (Pewitt et al., 1999). In the same study,
the presence of cycloheximide alone partially increased
the AM signal, probably by AM mRNA stabilization, as
suggested by other authors (Minamino et al., 1995).
Previous studies in vascular endothelial and smooth
muscle cells showed that androgens did not affect AM
expression (Imai et al., 1995; Minamino et al., 1995).
Indeed, studies by Pewitt et al. (1999) showed no AM
androgen regulation in organs other than the prostate
(including androgen-dependent organs such as the
seminal vesicles). Moreover, a genetic analysis of the 5
upstream region of the AM gene performed by Mi-
namino et al. (1995) failed to find any androgen re-
sponse element (ARE). Taken together, these results
suggest the existence of a prostate-specific transcrip-
tional mechanism that activates AM gene under andro-
gen control. However, further studies should be done in
order to clarify how this process occurs.
AM AND PAMP IN HUMAN PROSTATE:
IMPLICATIONS OF THEIR EXPRESSION IN
PROSTATE CARCINOMA
AM in Normal and Neoplastic Prostate
Similar to the rat prostate, AM is widely expressed in
the normal human prostate (Jime´nez et al., 1999). In
situ hybridization and immunocytochemical studies
show AM expression in the glandular epithelium of the
ducts and acini (mainly in the basal compartment)
(Fig. 4) and in the epithelium of the urethra, ejacula-
tory ducts, and squamous glands. Moreover, some stro-
mal cells, endothelial cells, and nerves are also stained
Fig. 4. Immunoreactivity for AM in human prostate.
a: In normal prostate, the basal compartment of the epi-
thelium is strongly stained. AM is also found in blood
vessels (arrow). 300. b: In prostate carcinoma, most
tumor cells are labeled with anti-AM antibody. 600.
[Color figure can be viewed in the online issue, which is
available at www.interscience.wiley.com.]
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for AM. Another similarity with the rat prostate is that
PAMP is only localized in NE cells (Jime´nez et al.,
1999).
AM is expressed in PCa as well (Fig. 4). Rocchi et al.
(2001) recently described the presence of AM in PCa
and suggested that AM expression is increased in cor-
relation with tumor progression, although few cases of
PCa were studied. In our hands, immunohistochemical
analysis did not show any correlation between AM
expression and tumor progression (Jime´nez et al., in
prep.).
Expression of AM mRNA has also been reported in
androgen-independent PCa cell lines PC-3 and DU-
145, but not in the androgen-dependent cell LNCaP
(Miller et al., 1996; Rocchi et al., 2001). However, we
have found preproAM mRNA in LNCaP (Jime´nez et
al., in prep.). The effect of AM on PCa cell proliferation
was analyzed by Rocchi et al. (2001). The addition of
2  10-7 M AM in the culture media had no effect on
LNCaP or PC-3 and produced a slight increase in DU-
145 growth after 8 days in culture. We have stably
transfected PC-3 cells with an expression vector carry-
ing the AM gene. Clones with different levels of AM
expression were analyzed to compare in vitro and in
vivo proliferation. Our results show that the ectopic
expression of AM inhibits proliferation of PC-3 cells,
both in vitro (60–80% inhibition) and in vivo (50–70%
inhibition, 5 weeks after injection in nude mice). More-
over, a G0/G1 cell cycle arrest and a reduction of an-
chorage-independent growth in soft agar were observed
in the PC-3-AM transfectants (Abasolo et al., in prep.).
New studies in this direction are needed to further
clarify the role of AM in growth control, in prostate
cancer cell lines and prostate tumors.
PAMP in Normal Human Prostate and in
Prostate Carcinoma
PAMP is only expressed in NE cells in normal and
neoplastic human prostate (Fig. 5) (Jime´nez et al.,
1999; 2001). In the normal prostate, NE cells express-
ing PAMP are more abundant in the utriculus and
urethra than in the glands. Moreover, the portion of
the glands located near the urethra contains more
PAMP-positive cells than the periphery. Unlike the rat
prostate, all the PAMP-stained cells colocalize with
CgA- and serotonin-NE cells in the human prostate.
However, not all the cells labeled for serotonin or CgA
were positive for PAMP, which shows that PAMP-NE
cells represent a subgroup of the NE population.
We have extensively examined the distribution of
PAMP staining in a variety of prostate tumors and PCa
xenograft models and quantified the number of NE
cells positive for PAMP in these samples (Jime´nez et
al., 2001). Clinical material included neoplastic tissues
obtained through radical prostatectomy (RPs) and
transurethral resection of the prostate (TURPs) with
different Gleason sum scores (GSS). Some of the pa-
tients undergoing TURP had been pretreated with an-
drogen-blockage therapy. PAMP was immunolocalized
in 80% of the prostate tumors from the clinical sam-
ples. The NE phenotype of PAMP-positive cells was
confirmed by colocalization with CgA. As previously
described for CgA (Noordzij et al., 1995), no significant
correlation was found between the number of PAMP-
positive cells and tumor grade, progression, or progno-
sis. However, we found that TURPs from patients pre-
treated with antiandrogens showed a significantly
higher number of PAMP-positive cells than TURPs
from untreated patients. This result shows that the
subpopulation of NE cells expressing PAMP increases
after androgen deprivation in PCa and points out that
this peptide might regulate androgen-independent pros-
tate tumor growth.
Previous studies on some human prostate tumors
xenografted into nude mice (PC-295 and PC-310 mod-
els) showed an extensive NE differentiation after cas-
tration (Jongsma et al., 1999, 2000). Both models (es-
pecially PC-310) exhibited a significant increase in
PAMP-positive cells after castration, which is in accor-
dance with our data on clinical TURPs (Jime´nez et al.,
2001). Unlike in PC-295, PAMP-positive NE cells dif-
ferentiated sharply in PC-310, in parallel with the CgA
population. Interestingly, PC-310 xenograft survives
much longer than PC-295 after androgen removal. We
hypothesized that the differences in survival time
could be due to the different PAMP expression program
(Jime´nez et al., 2001).
Coexpression of AM and PAMP With Amidating
Enzymes in the Human Normal Prostate
and in PCa
As mentioned above, AM and PAMP are amidated
peptides. Amidation, which is required for full activity
of many peptides and hormones, is performed by PAM.
The presence of PAM was initially described in the
prostate by Samos and Gkonos (1996) in rats. Rocchi et
al. (2001) recently reported the expression of PAM
mRNA in human prostate. They found a correlation in
the expression of PAM mRNA and AM mRNA in be-
nign hyperplastic prostates, prostate tumors, and PCa
cell lines. This result suggests that PAM enzyme could
modulate AM function through amidation (and, there-
fore, maturation) in human prostate. Studies in other
types of tumors have shown that increase in amidation
is frequently associated with increase in tumor growth
(Iwai et al., 1999).
Using a battery of antibodies against the PHM re-
gion of PAM enzyme in human prostate, we have im-
munolocalized PHM in NE cells of human normal and
neoplastic prostate (Jime´nez et al., 2001). All the NE
cells positive for the amidating enzyme were also
stained for CgA and many of them for PAMP. However,
there was not a complete colocalization between
PAMP- and PAM-positive cells. In fact, there were
more cells stained for PAMP than for PAM. Several
explanations can be given for these results. 1) The
presence of the PAM enzyme in the cells could be
transient. 2) Although our antibodies against PAMP
recognize its amidated form, they could partially label
the nonamidated peptide. 3) The antibodies used for
PAM might not recognize all the enzyme isoforms. De-
spite lacking a perfect match at the protein level, PAM
enzyme and PAMP seem to be expressed in a coordi-
nated way in normal prostate and in PCa (Jime´nez et
al., 2001).
CONCLUSIONS AND FUTURE DIRECTIONS
Recent studies have shown that AM and PAMP are
largely expressed in rat and human (normal and neo-
plastic) prostate, although in different cellular com-
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partments. These results suggest that both peptides
might have a significant role in the biology of normal
and tumoral prostate. However, many unresolved
questions arise from these studies. In particular, some
important issues should be addressed in the future: 1)
the mechanisms responsible for the differential expres-
sion of AM and PAMP in the prostate; 2) the concrete
physiological role of these peptides in both normal and
neoplastic prostate; 3) the characterization of the re-
ceptors that mediate AM/PAMP functions; and 4) the
intracellular pathways activated by AM/PAMP.
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